News

Enlarge image

RegulatoryDenmarkEUGermanyUK

EC fines pharma companies

20.06.2013 - The European Commission has fined five pharma companies for delaying market entry of generic versions of the anti-depressant citalopram.

Danish drugmaker H.Lundbeck has to pay €93.8m, while the fine for German Merck KGaA/Generics is €21.4, its former subsidiary Generics UK pays €7.7m, while Arrow (now part of Zoetis), Alpharma (now part of Actavis), and Ranbaxy total € 52.2m in fines. According to investigations of the EC, in 2002, Lundbeck agreed with each of the generics makers to delay the market entry of cheaper versions of Lundbeck's branded citalopram, a blockbuster antidepressant.  

"It is unacceptable that a company pays off its competitors to stay out of its market and delay the entry of cheaper medicines“, stressed Commission Vice-President Joaquín Almunia. „Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints. The Commission will not tolerate such anti-competitive practices".  “We are surprised and disappointed that the EC has reached this erroneous conclusion, which we totally disagree with, and it is therefore our intention to appeal,” stressed Lundbeck’s CEO Ulf Wiinberg. “It is wrong and extremely misleading to claim that these agreements have delayed the marketing of citalopram copies and thereby violated competition laws,” said Wiinberg. The agreements were meant to protect against patent infringements by the generic companies, he said.  Ranbaxy stated that the Commission misunderstood the facts. 

Citalopram was Lundbeck's best-selling product at the time. After Lundbeck's basic patent for the citalopram molecule had expired, it only held a number of related process patents which provided a more limited protection. Producers of cheaper, generic versions of citalopram therefore had the possibility to enter the market, which would have brought down the price for the medicine by approximately 90%.  According to the Commission, the generic producers agreed with Lundbeck in 2002 not to enter the market in return for substantial payments and other inducements from Lundbeck amounting to tens of millions of euros. 

Internal documents refer to a "club" being formed and "a pile of $$$" to be shared among the participants. Lundbeck paid significant lump sums, purchased generics' stock for the sole purpose of destroying it, and offered guaranteed profits in a distribution agreement. The agreements gave Lundbeck the certainty that the generics producers would stay out of the market for the duration of the agreements without giving the generic producers any guarantee of market entry thereafter. These agreements are very different from other settlements of patent disputes where generic companies are not simply paid off to stay out of the market.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/ec-fines-pharma-companies.html

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEWRON (CH)18.50 CHF9.14%
  • GENMAB (DK)1210.00 DKK5.68%
  • VALNEVA (F)2.42 EUR5.68%

FLOP

  • KAROLINSKA (S)7.30 SEK-3.95%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • SAREUM HOLDINGS (UK)0.60 GBP-3.23%

TOP

  • PROTHENA PLC (IE)51.61 USD42.6%
  • PHARMING (NL)0.25 EUR31.6%
  • ACTIVE BIOTECH (S)11.95 SEK29.2%

FLOP

  • MOLOGEN (D)1.80 EUR-37.9%
  • SANTHERA (CH)56.40 CHF-20.6%
  • EVOCUTIS (UK)0.04 GBP-20.0%

TOP

  • KARO BIO (S)31.10 SEK1906.5%
  • NICOX (F)11.17 EUR481.8%
  • SAREUM HOLDINGS (UK)0.60 GBP172.7%

FLOP

  • BB BIOTECH (D)44.69 EUR-84.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.87 SEK-77.6%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 27.07.2016